Inhibikase Therapeutics, Inc. — Fiscal 2022 Form 10-K Summary
Reporting period: Year ended December 31, 2022. The filing was dated March 31, 2023; the request refers to 2022 Q4, but this is an annual Form 10-K rather than a standalone quarterly filing.
Business Context and Development Status
Inhibikase is a clinical-stage pharmaceutical company developing protein kinase inhibitors, with primary programs targeting Parkinson’s disease and related neurodegenerative disorders. The lead candidate, IkT-148009, is a brain-penetrant c-Abl inhibitor being evaluated in Parkinson’s disease, gastrointestinal complications associated with Parkinson’s disease, and Multiple System Atrophy (MSA). IkT-001Pro is a prodrug of imatinib being developed for stable-phase chronic myelogenous leukemia through a proposed FDA 505(b)(2) pathway.
- The Phase 2a Parkinson’s “201” trial began in May 2022.
- An IND for MSA was filed in 2022. The FDA placed the Parkinson’s and MSA IkT-148009 programs on full clinical hold on November 7, 2022.
- The FDA lifted the hold for the Parkinson’s program in January 2023 and for MSA in March 2023, subject to additional ophthalmologic monitoring and other commitments.
- IkT-001Pro entered clinical development in 2022 under an IND cleared by the FDA. Three of four planned dose cohorts had been completed by the filing date.
- The company has no approved products and has generated no product-sales revenue.
Financial Performance and Key Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Grant revenue | $123,440 | $3,100,605 | Down 96.0% |
| Research and development expense | $12,034,985 | $11,359,104 | Up 6.0% |
| Selling, general and administrative expense | $6,217,063 | $6,507,641 | Down 4.5% |
| Loss from operations | $(18,128,608) | $(14,766,140) | Loss increased |
| Net loss | $(18,054,155) | $(14,786,063) | Loss increased 22.1% |
| Net loss per share | $(0.72) | $(0.81) | Improved primarily from higher share count |
| Net cash used in operating activities | $(17,351,103) | $(14,297,051) | Use increased |
| Net cash used in investing activities | $(16,005,708) | $— | Primarily Treasury purchases |
| Net cash from financing activities | $(204,769) | $41,093,671 | Prior year included equity offering proceeds |
Research and development represented approximately 66% of operating expenses in 2022. Program-specific R&D expense was $9.65 million for Parkinson’s disease, $468,016 for MSA, and $1.46 million for CML.
At December 31, 2022, the company had cash and cash equivalents of $7.19 million, marketable securities of $15.86 million, total current assets of $24.37 million, total liabilities of $3.90 million, working capital of $20.68 million, and stockholders’ equity of $21.04 million. Marketable securities consisted of U.S. Treasury obligations and generated $104,718 of unrealized gains recognized in other comprehensive income.
The company had no notes payable at year-end after repaying the CEO note, including accrued interest, on January 3, 2022. Lease liabilities totaled approximately $351,288 at December 31, 2022. The company reported an accumulated deficit of $47.87 million.
Material Changes Versus the Prior Comparable Period
- Grant revenue declined by $2.98 million as the company shifted resources from grant-supported research toward clinical programs.
- R&D expense increased by $676,000, primarily due to non-grant activities and the Phase 2a Parkinson’s trial.
- SG&A decreased by $291,000, principally because of lower warrant and stock-based compensation expense, partially offset by higher legal, regulatory, compliance, and other operating costs.
- Operating cash use increased by approximately $3.05 million and net loss increased by approximately $3.27 million.
- The company invested $20.73 million in marketable securities and received $4.96 million from maturities, resulting in net investing cash use of $16.01 million.
- Common shares outstanding increased from 25.16 million at December 31, 2021 to 25.23 million at December 31, 2022. The filing reported 28.98 million shares outstanding as of March 14, 2023.
- In January 2023, the company raised approximately $8.7 million in net proceeds through a registered direct offering and concurrent private placements involving common stock and warrants.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management estimated that year-end 2022 working capital plus the January 2023 financing would fund normal operations into the fourth quarter of 2024. This estimate depends on assumptions that may prove inaccurate, and the company states that additional capital will be required.
- The company expects continuing losses and negative operating cash flows for the foreseeable future and may need additional equity, debt, grant, licensing, or collaboration financing.
- The Parkinson’s 201 trial was expected to restart initially at 50 mg and 100 mg, with a potential 200 mg arm after submission and review of additional safety and steady-state pharmacokinetic data.
- The proposed MSA Phase 2 study depends on positive results from animal-model studies. If those studies do not demonstrate therapeutic benefit, the clinical study will not proceed.
- IkT-001Pro dose-finding and dose-equivalence work was expected to continue through the second quarter of 2023, followed by FDA discussions regarding the NDA pathway and a potential superiority study against 400 mg imatinib.
- Preclinical studies identified retinal and other eye findings in rats treated with IkT-148009. The FDA requested expanded ocular monitoring, including visual acuity and examination of the cornea and lens.
- The company received Nasdaq deficiency notices related to the $1.00 minimum bid-price requirement and stated that a reverse stock split might be required to regain compliance. Failure to regain compliance could result in delisting.
- All revenue in 2022 and 2021 came from a single source, the U.S. government, through federal research grants.
- The company relies heavily on contract research organizations, academic institutions, and third-party manufacturers, including manufacturers located in China.
- All novel and in-licensed compounds were funded in whole or in part by the U.S. government and may be subject to federal march-in rights and related obligations.
- The Sphaera agreement includes potential milestone payments totaling up to $5.625 million and mid-single-digit royalty obligations, although no milestones had been achieved or paid. The company stated that it was renegotiating certain financial obligations with Sphaera.
- The financial statements were prepared on a going-concern basis. Management’s ability to continue operations depends on obtaining additional capital, regulatory progress, and successful development and commercialization of product candidates.
Most Important Facts for Investors to Verify
- Whether the FDA’s lifting of the IkT-148009 clinical holds remains effective and whether additional ocular monitoring identifies new safety issues.
- Progress, enrollment, dosing, and efficacy outcomes in the Parkinson’s 201 trial and any future MSA trial.
- Whether IkT-001Pro achieves bioequivalence and a demonstrated safety advantage over standard imatinib sufficient to support a 505(b)(2) NDA.
- Actual cash burn, marketable-securities liquidity, and the duration of available capital relative to the company’s stated fourth-quarter 2024 runway.
- The terms, dilution, exercise activity, and potential overhang from the January 2023 common-stock and warrant financing.
- Nasdaq listing compliance and whether a reverse stock split or further financing is required.
- Dependence on federal grants, third-party manufacturers, China-related supply chains, and the ability to secure additional funding.
- Patent ownership, expiration dates, Sphaera and Emory obligations, government march-in rights, and any future licensing or royalty liabilities.